Best Neurology Companies in Spain
The 44 best Neurology companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: INBRAIN Neuroelectronics.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Spain
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INBRAIN Neuroelectronics Developer of implantable neurotechnology for decoding and modulating brain activity | $83M | 15 mo ago | 52 | 2019 | Kostas Kostarelos Co-Founder | WordPressPleskMySQL+17 | 43 patents Implantable neural electrodes and brain neurostimulation systems for therapeutic neuromodulation | — |
| 2 | Anaconda Biomed Developer of medical devices for mechanical thromboectomy procedures | $39M | 80 mo ago | 28 | 2015 | Ofir Arad Co-Founder & Managig Director | WordPressApple iCloud MailGoogle Workspace+15 | 101 patents Intravascular thrombectomy and clot‑removal devices, including expandable catheters and attachment systems. | — |
| 3 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 32 mo ago | 15 | 2009 | Raul Insa Founder & CEO | — | 117 patents Pharmaceutical compounds and formulations for treating dystrophinopathies, movement disorders, and PKU | — |
| 4 | ORYZON Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology… | $25M | 16 mo ago | 43 | 2000 | Carlos Buesa CEO | DrupalApple iCloud MailMicrosoft 365+10 | — | — |
| 5 | Neuroelectrics Provider of wireless EEG monitoring and brain stimulation devices | $18M | 67 mo ago | 62 | 2011 | Ana Valls CEO | Wix eCommerceCart FunctionalityWix+17 | — | 1 partnership |
| 6 | ADmit Therapeutics Provider of diagnostic services for early detection of Alzheimer's disease | $13M | 34 mo ago | 10 | 2017 | Jordi Gascon Co-Founder | — | 18 patents Biomarker-driven nucleic acid diagnostics for Lewy body dementia and Alzheimer risk assessment | — |
| 7 | Laminar Pharma Developer of melipathy based drugs | $12M | 25 mo ago | 30 | 2006 | — | WordPressPleskMySQL+29 | — | — |
| 8 | Araclon Develop immunotherapy and diagnostic tests for neurodegenerative disorders | $11M | 206 mo ago | 29 | 2004 | — | WordPressPleskMySQL+17 | — | — |
| 9 | nLife Therapeutics Oligonucleotide-based therapies for Parkinsons's disease and other CNS disorders | $9M | 146 mo ago | 17 | 2010 | — | — | 46 patents Targeted nucleic acid delivery systems for neurons and hepatic cells | — |
| 10 | Accure Therapeutics Developer of therapeutics to treat CNS diseases | $8M | 75 mo ago | 12 | 2020 | Laurent Nguyen Cong Duc Chief Executive Officer | — | 41 patents Small-molecule gelatinase (MMP) inhibitors for treating neurological disorders | — |
| 11 | Tetraneuron Developer of gene therapies to treat Alzheimer's disease | $5M | 43 mo ago | 15 | 2012 | Jose Frade Co-Founder | WordPressMySQLPHP+21 | 9 patents Predictive biomarkers for Alzheimer's disease risk assessment | — |
| 12 | Connecta Therapeutics Developer of drugs for treating neurological disorders | $5M | 30 mo ago | 4 | 2018 | Jordi Fabrega Co-Founder & CEO | — | — | — |
| 13 | Raman Health Technologies Developer of a diagnostics platform for the diagnosis of neurodegenerative diseases | $4M | 129 mo ago | — | 2013 | Carlo Zanotti CEO | — | 7 patents Alzheimer's disease diagnostics using biomarker detection in biological samples | — |
| 14 | Methinks Provider of AI and cloud-based software for the diagnosis of strokes | $3M | 4 mo ago | 17 | 2016 | Cristian Marti Founder | WebflowApple iCloud MailMicrosoft 365+12 | — | — |
| 15 | Irisbond Developer of eye tracking solution to control a computer for disabled individuals 32Growth top 35%Talent bottom 49%Market bottom 43%Funding bottom 42% All 7 signals ▾Growthtop 35% Talentbottom 49% Marketbottom 43% Fundingbottom 42% Globalbottom 29% Techbottom 26% Newsbottom 22% Growth: Fresh capital in last 24 mo Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $2M | 17 mo ago | 46 | 2013 | Eduardo Torrecilla Founder & CEO | WordPressMySQLPHP+12 | — | 1 job opening |
| 16 | Bitbrain Provider of brain-sensing devices for research purposes | $2M | 65 mo ago | 45 | 2010 | Maria Lopez Valdes Co-founder & CEO | Node.jsUbuntuVideoJS+12 | — | 3 launchs · 1 partnership |
| 17 | HemoPhotonics Provider of non-invasive and real-time blood flow monitoring devices | $2M | 67 mo ago | — | 2013 | Udo Weigel CEO | — | 3 patents Non‑invasive pulsatile blood‑flow analysis for medical diagnosis and pathology classification. | — |
| 18 | Aromics Biotechnology company that specialises in functional genomics and proteomics technologies | $2M | 93 mo ago | 4 | 2010 | Carme Plasencia Owner & CEO | — | — | — |
| 19 | ALA Diagnostics Developer of invitro diagnostic kits for the detection of multiple sclerosis | $1M | 38 mo ago | — | 2019 | Jose Ramon Montero Founder | — | — | — |
| 20 | Licbiotech Developer of diagnostic tools and therapeutics for neurological diseases | $749K | 44 mo ago | — | 2017 | — | TypeScriptGoogle CloudZone.js+10 | — | — |
| 21 | MJN Neuroserveis Developer of a wearable device that evaluates the risk of epileptic seizures | $631K | 58 mo ago | 22 | 2014 | Salva Gutierrez Co-Founder & Co-CEO | WordPressMySQLPHP+19 | 9 patents Real-time monitoring and prediction devices for neurological disorders, especially epilepsy. | — |
| 22 | Freeox Biotech Developer of therapies for treating ischaemic stroke | $573K | 93 mo ago | 2 | 2017 | Angel Honrado Co-Founder | — | — | — |
| 23 | QMENTA AI-powered cloud-based solutions for clinical trials and studies | $555K | 99 mo ago | 43 | 2013 | Vesna Prchkovska Co-Founder & COO | — | — | 1 job opening · 1 launch |
| 24 | ONeSTX Developer of drugs to treat neurodegenerative diseases | $113K | 15 mo ago | — | 2020 | Angel Ramirez CEO | — | — | — |
| 25 | Taniwa Solutions Platform for neurological evaluation to perform early detection of neurodegenerative issues | $110K | 130 mo ago | 10 | 2012 | Manuel Guillermo Fraga Castro Co-Founder & CFO | — | — | — |
| 26 | AURA Innovative Robotics Diagnostic tool for neurological and mental disorders | $110K | 109 mo ago | 8 | 2015 | Rafael Acebron Lopez Co-Founder | — | — | — |
Top 12 Neurology companies in Spain
#1
Series B · Barcelona, Catalonia · founded 2019 · 52 employees$82.8Mraised▾
Developer of implantable neurotechnology for decoding and modulating brain activity. The company focuses on creating bi-directional, high-resolution brain-computer interfaces. These interfaces enable real-time smart neural decoding and modulation in closed loop. The company's platform combines hardware and data analytics to personalize therapy.
- May 2025Grant (prize money)$4.5M
- Oct 2024Series B$50M
- Dec 2023Venture Debt$22.1M
- Oct 2023Series A—
#2
Seed · Barcelona, Catalonia · founded 2016 · 17 employees$2.7Mraised▾
Methinks provides AI and cloud-based software for the diagnosis of strokes. It allows the radiologist to assess stroke treatment from a non-contrast CT. It also provides a communication feature that allows coordination among hospitals, stroke units, and healthcare professionals.
- Nov 2023Seed—
- Feb 2023Grant (prize money)$2.7M
- Dec 2020Grant (prize money)—
#3
Public · Barcelona, Catalonia · founded 2000 · 43 employees$24.9Mraised▾
Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology platforms. It uses a proprietary epigenetic platform to identify drug targets for cancer and neurodegenerative diseases. Its lead candidate targets lysine-specific demethylase - 1 (LSD-1) for Alzheimer's, Parkinson's, Huntington's, and certain other rare diseases.
- Apr 2025Post IPO$34.1M
- Sep 2021Grant (prize money)$1M
- Jul 2019Post IPO$22.3M
- Mar 2017Post IPO$19.5M
#4
Series A · San Sebastian, Basque Country · founded 2013 · 46 employees$2.1Mraised▾
Developer of eye tracking solution to control a computer for disabled individuals. The companys technology uses IR light beams which generate flashes in the users cornea, which is identified via a computer algorithm to operate the computer with the movement of the eyes. Its offerings include Irisbond eye-tracking camera, application to control computers and tablets with eyes, a grid style menu for access via eye-tracking.
- Mar 2025Series A$4.9M
- Nov 2023Seed$2.1M
#5
Series A · Palma, Balearic Islands · founded 2006 · 30 employees$12Mraised▾
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimer’s, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
- Jul 2024Series A$6.3M
- Oct 2023Series A$8.4M
- Nov 2022Grant (prize money)$280.5K
- Apr 2021Grant (prize money)$189.4K
#6
Series B · Barcelona, Catalonia · founded 2009 · 15 employees$28.5Mraised▾
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
- Dec 2023Series B$18.5M
- Mar 2019Series A$7.9M
- Jan 2017Seed$2.1M
#7
Series A · Barcelona, Catalonia · founded 2017 · 10 employees$12.9Mraised▾
Provider of diagnostic services for early detection of Alzheimer's disease. The company is developing diagnostic tests by using next-generation sequencing analysis for the detection of biomarkers β-amyloid nor tau. The test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA.
- Oct 2023Series A$5.7M
- Jan 2021Grant (prize money)$3M
- Aug 2020Series A$5M
- Mar 2019Seed$2.3M
#8
Seed · Barcelona, Catalonia · founded 2018 · 4 employees$4.9Mraised▾
CONNECTA THERAPEUTICS is a developer of drugs for treating neurological disorders. It has developed a CTH120 drug for the treatment of fragile X neurological disorder syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are currently no therapeutic interventions available. The molecule has been proven in vitro tests and in vivo in animal models can treat other neurodevelopmental disorders such as Rett syndrome, Down syndrome, and autism spectrum disorders, among others.
- Feb 2024Seed$2.9M
- Sep 2020Seed$2M
#9
Seed · Seville, Andalusia · founded 2020$112.6Kraised▾
Developer of drugs to treat neurodegenerative diseases. The company's lead product is ONESTX-1 a combination with specific sulfated neurosteroid hormones such as DHEA-S for Parkinson's disease (PD) and Huntington's disease (HD).
- May 2025Seed$112.6K
#10
Series B · Barcelona, Catalonia · founded 2015 · 28 employees$39Mraised▾
Developer of medical devices for mechanical thromboectomy procedures. It focuses on creating catheters intended for removing blood clots. The device the ANA Advanced Neurovascular Access system includes the latest ANA5 Funnel Catheter which is designed to enhance clot retrieval procedures by combining aspiration with flow restriction for effective mechanical thrombectomy.
- Dec 2019Series B$22.2M
- Aug 2018Grant (prize money)—
- May 2017Series A$16.8M
#11
Series A · Barcelona, Catalonia · founded 2011 · 62 employees$17.9Mraised▾
Neuroelectrics is a provider of wireless EEG monitoring and brain stimulation devices. It combines EEG monitoring and transcranial brain stimulation in wireless and non-invasive devices. The technology has applications in the management of neuropathic pain, computer-brain interfaces, and cognitive enhancement.
- Jan 2021Grant (prize money)$1M
- Nov 2020Series A$17.9M
- Jun 2020Grant (prize money)$3.3M
- Jun 2017Grant (prize money)—
#12
Series A · Valencia, Valencian Community · founded 2012 · 15 employees$5Mraised▾
Developer of gene therapies to treat Alzheimer's disease. It offers a dominant-negative form of E2F4 incapable of being phosphorylated by p38MAPK to prevent the neuronal tetraploidy. It offers pipeline of drug candidates which include TET-101 for Alzheimers, TET-E2F4DH for glaucoma, parkinsons, and aging.
- Dec 2022Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Spain
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 675 Spain-affiliated papers.
- Biomedical Research Networking Center on Neurodegenerative Diseases98
- Clinica Universidad de Navarra34
- Centro de Investigación Biomédica en Red de Salud Mental33
- Instituto de Salud Carlos III33
- Universidad de Navarra31
- Stimulation3→14
- Deep brain stimulation9→16
- Neurostimulation1→7
- Neuromodulation1→6
- Brain stimulation2→7
- Neuromodulation5→21
- Brain stimulation3→16
- Parkinson's disease25→37
- Thalamotomy1→13
- Essential tremor8→17
- Neuromodulation2→9
- Stimulation5→10
- Neurostimulation4→8
- Neurosurgery3→6
- Deep brain stimulation32→34
Where neurotech is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.